Precise Bio, a North Carolina based Regenerative Medicine company announced the launch of a dedicated ophthalmology business unit in its Winston-Salem facility. In addition to its scalable platform that enables mass-bio-fabrication of tissue and organ, Precise Bio utilize its biological and technological capabilities to form strategic partnerships with established healthcare companies, aiming to advance 3D bioprinting research for the eyes and bring them to market.
“As the first company to transplant a 3D-printed corneal graft in animals, we are uniquely positioned to advance the use of bio-printed tissues in ophthalmology,” said Aryeh Batt, co-founder and Chief Executive Officer of Precise Bio. “Establishing a business unit dedicated to realizing this potential will support our future financing strategies and ensure that our financial resources are aligned with the tremendous power of our technology and intellectual property in a market with an estimated cumulative value of $10 billion.”
Precise Bio has developed an innovative 4D-bio-fabrication technology that is a platform for comprises cell expansion, bio-materials, processes, printing technology. Key advantages of this platform compared with other bio-fabrication approaches are that it is able to generate complex tissues in a highly reproducible manner and to apply lessons learned from the fabrication of one tissue to the next. This platform can solve critical limitations of existing 3D bio-printing technologies and is paving the way for the engineering of more complex tissues and organs.
Precise Bio is the first company to 3D bio-print a human cell-based cornea graft and transplant it to an animal. Results of the initial study support the feasibility, safety and efficacy of Precise Bio’s novel technologies and establish a foundation for future development and progress toward human trials. The company’s robust technology platform allows it to advance its printed human cornea program concurrent with the development of other organs and tissues for use in ophthalmic indications. This comprises a broad array of possibilities including retinal patch, vision correction lenticules, solutions for ocular surface diseases and others.
Precise Bio’s 4D Bio Fabrication Platform built around its proprietary Laser-Assisted bio-printing technology. Credit: Precise Bio
“Precise Bio’s technology has the potential to truly transform the treatment of serious diseases, and to address the unmet needs in corneal replacement and other indications, which cannot be met by the limited number of donor tissues and organs,” said Shay Soker, PhD, Professor at the Wake Forest Institute of Regenerative Medicine (WFIRM) and a co-founder of Precise Bio. “The company’s technology overcomes multiple challenges in scalable, reproducible manufacturing of bio-printed tissues and organs, and positions Precise Bio for leadership in the field of regenerative medicine.”